SLAMF7 was also chosen as a target over other myeloma markers, such as B-cell maturation antigen (BCMA) and CD38, because BCMA expression can be downregulated or lost entirely in patients who have undergone BCMA-targeted therapies [18]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.